Novo Nordisk shares climb as amycretin shows promising trial resultsJanuary 24, 2025 Novo Nordisk’s amycretin shows up to 22% weight loss in trials, boosting its stock by 6.87% as the drug exhibits safety and potential as a next-gen obesity treatment.
Novo Nordisk tops Tesla in market value with new obesity pillMarch 8, 2024 Novo Nordisk edges past Tesla in market value on successful obesity pill trial. Danish company’s shares soar.
